Tristel (GB:TSTL) has released an update.
Tristel PLC has reported a remarkable financial performance for the year ending June 2024, with record revenues and a 38.5% increase in pre-tax profits, driven by strong demand for its infection prevention products. The company remains debt-free and continues to expand its market presence, particularly in North America, following FDA clearance for its disinfectant products. With a new CEO at the helm, Tristel is poised for further growth, backed by its innovative offerings and strategic market expansions.
For further insights into GB:TSTL stock, check out TipRanks’ Stock Analysis page.
